BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

...and visionary initiative created and pulled through by founder and chief innovation officer, Clive Meanwell, MedCo...
...shouldn’t be making cost-effectiveness decisions before it is ready to act on them. Meanwell and MedCo...
BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

...at Express Scripts Holding Co. (NASDAQ:ESRX) and market group CFO/VP - national accounts group at Medco...
BioCentury | Sep 7, 2015
Strategy

Back to School 2015: Changing the subject

...better outcomes. "A payer would want to see data," said Robert Epstein, former CMO at Medco...
BioCentury | Feb 23, 2015
Company News

AstraZeneca pl pharmaceuticals news

...U.S. government $7.9 million to settle allegations that it engaged in a kickback scheme with Medco...
...violation of the False Claims Act. Express Scripts Holding Co. (NASDAQ:ESRX, St. Louis, Mo.) acquired Medco...
BioCentury | Sep 2, 2013
Strategy

Back to School 2013: Facing reality

For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices Agency are...
BioCentury | Jul 15, 2013
Company News

Vivus endocrine/metabolic news

...it amended its agreements with Express Scripts Holding Co. (NASDAQ:ESRX, St. Louis, Mo.) and Express' Medco...
...where Qsymia is offered on Tier 2 will have a co-pay of $25-$30 per month. Medco...
BioCentury | May 27, 2013
Clinical News

Gattex regulatory update

...Cigna Corp. (NYSE:CI, Bloomfield, Conn.), Express Scripts Holding Co .(NASDAQ:ESRX, St. Louis, Mo.), Express Scripts' Medco...
BioCentury | May 20, 2013
Company News

Vivus, Express Scripts sales and marketing update

...Vivus said obesity drug Qsymia phentermine/topiramate was added to the national formulary for Express Scripts' Medco...
BioCentury | Apr 15, 2013
Company News

Medco, University of Ferrara deal

...which develops cardiovascular medicines and adenosine-based products, will own intellectual property derived from the collaboration. Medco Research Inc....
BioCentury | Jan 7, 2013
Company News

Valeant Pharmaceuticals management update

...and an EVP, effective Feb. 1, formerly SVP of consumer solutions and retail markets at Medco...
Items per page:
1 - 10 of 170
BioCentury | Feb 12, 2020
Politics, Policy & Law

When single-payer systems adopt innovation better than U.S. commercial payers

...and visionary initiative created and pulled through by founder and chief innovation officer, Clive Meanwell, MedCo...
...shouldn’t be making cost-effectiveness decisions before it is ready to act on them. Meanwell and MedCo...
BioCentury | Jan 10, 2020
Company News

Management tracks: COO, CMO depart as Solid restructures; plus Abeona, Millendo, Immuneering, Akouos, Kintai, Macrophage, Selexis, Prime

...at Express Scripts Holding Co. (NASDAQ:ESRX) and market group CFO/VP - national accounts group at Medco...
BioCentury | Sep 7, 2015
Strategy

Back to School 2015: Changing the subject

...better outcomes. "A payer would want to see data," said Robert Epstein, former CMO at Medco...
BioCentury | Feb 23, 2015
Company News

AstraZeneca pl pharmaceuticals news

...U.S. government $7.9 million to settle allegations that it engaged in a kickback scheme with Medco...
...violation of the False Claims Act. Express Scripts Holding Co. (NASDAQ:ESRX, St. Louis, Mo.) acquired Medco...
BioCentury | Sep 2, 2013
Strategy

Back to School 2013: Facing reality

For the first time since the 2008 meltdown, nearly everything appears to be coming up roses for biopharma. Money is again flowing into the sector, FDA , EMA and Japan's Pharmaceuticals and Medical Devices Agency are...
BioCentury | Jul 15, 2013
Company News

Vivus endocrine/metabolic news

...it amended its agreements with Express Scripts Holding Co. (NASDAQ:ESRX, St. Louis, Mo.) and Express' Medco...
...where Qsymia is offered on Tier 2 will have a co-pay of $25-$30 per month. Medco...
BioCentury | May 27, 2013
Clinical News

Gattex regulatory update

...Cigna Corp. (NYSE:CI, Bloomfield, Conn.), Express Scripts Holding Co .(NASDAQ:ESRX, St. Louis, Mo.), Express Scripts' Medco...
BioCentury | May 20, 2013
Company News

Vivus, Express Scripts sales and marketing update

...Vivus said obesity drug Qsymia phentermine/topiramate was added to the national formulary for Express Scripts' Medco...
BioCentury | Apr 15, 2013
Company News

Medco, University of Ferrara deal

...which develops cardiovascular medicines and adenosine-based products, will own intellectual property derived from the collaboration. Medco Research Inc....
BioCentury | Jan 7, 2013
Company News

Valeant Pharmaceuticals management update

...and an EVP, effective Feb. 1, formerly SVP of consumer solutions and retail markets at Medco...
Items per page:
1 - 10 of 170